SecBot SecBot

OCUL

OCULAR THERAPEUTIX, INC
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001393434 Biotech & Drug Discovery
$6.01 −0.20 (−3.22%)
Nov 16 4:00 PM ET · prev $6.21
Market cap
$1.4B
Small cap
Consensus
Buy
95% Buy or better · 19 analysts
Median target
$28.00
+366% · range $14.00–34.00
1 year
−49.5%
from $11.89 · Nov 17
30 days
−4.5%
from $6.29
52-week range
$6.01–16.11
at the low
Avg volume 20D
2.52M
shares / day
Short interest
29.00M
≈13.2% of shares · +0.8%
Days to cover
10.1
at average volume
Insider net
−$2.5M
1 buyer · 8 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
17
analyzed by SecBot
SecBot read BEARISH 8 reports · 90 days
Balance 1 bearish · 0 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 6/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

  • Feb 2 to Feb 4 ▼ 2 days of insider sells: $101.4K by 1 insider, avg $8.82
  • Feb 12 ▼ 4 insiders sell $1.4M at $9.04
  • Feb 20 ▲ 1 insider buy $461.4K at $7.66
  • Feb 20 to Feb 23 ▼ 2 days of insider sells: $256.4K by 5 insiders, avg $8.22
  • Apr 13 ▲ Ocular Therapeutix presented additional Week 52 post-hoc data from i…
  • May 26 ▼ 4 insiders sell $237.8K at $8.20
  • Jun 3 ▼ 1 insider sell $122.6K at $8.27
  • Jun 4 FDA: Ocular Therapeutix™ to Participate in Clinical Trials at t…
  • Aug 24 to Aug 31 ▼ 2 days of insider sells: $333.1K by 5 insiders, avg $10.75
  • Oct 2 to Oct 8 ▼ 2 days of insider sells: $234.4K by 3 insiders, avg $7.14
  • Oct 12 UBS initiates
  • Nov 5 ▼ 1 insider sell $231.7K at $6.55

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $461.4K at an average $7.66. 8 insiders sold $2.9M. Price is 22% below their cost.

  • InstitutionsMIXED

    Q3 2026: 21 added (0 new), 15 trimmed or exited.

  • AnalystsBULLISH

    18 of 19 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.388 → −$0.355 over 90 days. 4 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +0.8% to 29.00M shares. 10.1 days to cover, ≈13.2% of shares.

  • TrendDOWNTREND

    24% below its 50-day average. New closing low $6.01 on Nov 16.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 10.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
MARSHALL WACE, LLPDOUBLED2,706,184$20.8M
UBS Group AGADD2,125,331$16.3M
Invesco Ltd.ADD1,844,269$14.1M
RAYMOND JAMES FINANCIAL INCADD1,346,461$10.3M
BNP PARIBAS FINANCIAL MARKETSDOUBLED698,960$5.4M
BNP Paribas Asset Management Holding S.A.ADD647,782$5.0M
RENAISSANCE TECHNOLOGIES LLCADD540,900$4.1M
Squarepoint Ops LLCTRIM486,212$3.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 95% rate it Buy or better
Strong Buy6Buy12Hold1Sell0Strong Sell0
12-month targets · 11 analysts

Price is below the lowest target. Median implies +366%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 10, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 19, 2026Needham
REITERATE
REITERATEBuy
Oct 12, 2026UBS
INITIATE
INITIATEBuy
Oct 2, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Sep 29, 2026Needham
REITERATE
REITERATEBuy
Sep 16, 2026Chardan Capital
MAINTAIN
MAINTAINBuy

Washington

Corporate Lobbying

1 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$461.4K
bought · 1 insider
$2.9M
sold · 8 insiders
−21.5%
vs their $7.66 cost
DateInsiderTypeValue
Nov 6, 2026
Sherif Riad
Director
Nov 6, 2026
AWARD88,000 sh
Nov 6, 2026
Sherif Riad
Director
Nov 6, 2026
AWARD28,000 sh
Nov 5, 2026
Saroj Namrata
Chief Business Officer
Nov 5, 2026
SELL$231.7K
Oct 8, 2026
Anderman Todd
Chief Legal Officer
Oct 8, 2026
SELL$87.4K
Oct 2, 2026
Heier Jeffrey S.
Chief Scientific Officer
Oct 2, 2026
SELL$76.6K
Oct 2, 2026
Kaiser Peter
Chief Development Officer
Oct 2, 2026
SELL$70.4K
Aug 31, 2026
Notman Donald
Chief Operating Officer
Aug 31, 2026
SELL$11.3K
Aug 25, 2026
Dugel Pravin
See Remarks
Aug 25, 2026
GIFT50,092 sh

Earnings setup

Estimates
−$0.35
EPS estimate, this quarter
+8%
estimate change, 90 days
4↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.35-$0.37–-$0.30-0.8%$13.7M
Next Q-$0.38-$0.43–-$0.34-4.5%$12.3M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Reddit Mentions per day, 14 days
Recent posts
All social signals and their track records

Short side

FINRA· Oct 30, 2026
28,998,345
shares short
+0.8%
vs prior settlement
10.1
days to cover
≈13.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 SEC
Riad Sherif filed an initial statement of beneficial ownership (Form 3) with Ocular Therapeutix, reporting no…
3 · Impact 2/10
Nov 9, 2026 SEC
Ocular Therapeutix elected Riad Sherif, M.D. to its board effective November 6, 2026, and received notice that…
8-K · Impact 2/10
Nov 9, 2026 SEC
Ocular Therapeutix reported Q3 2026 net loss of $(0.42) per share on revenue of $12.9M, missing the consensus EPS…
PRESS-RELEASE · Impact 5/10
Nov 9, 2026 Earnings
Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights
AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 sa
Nov 6, 2026 Insider
Sherif Riad was granted 88,000 shares
Director
Nov 6, 2026 Insider
Sherif Riad was granted 28,000 shares
Director
Nov 5, 2026 Insider
Saroj Namrata sold 35,370 shares
Chief Business Officer @ $6.55 ($231.7K)
Sep 30, 2026 Inst.
MARSHALL WACE, LLP · DOUBLED
2,706,184 shares ($20.8M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

17 filings · 3 press releases · 2 bullish · 1 bearish · 3 mixed · 11 neutral
All OCUL filing & press-release reports (20)